BACKGROUND AND PURPOSE: Natalizumab discontinuation induces the recurrence of multiple sclerosis disease activity: currently no therapeutic approach has been found able to abolish disease reactivation. METHODS: The recurrence of disease activity after natalizumab discontinuation was retrospectively evaluated in 79 patients who had been treated with immunomodulating agents, other first-line therapies, fingolimod or not treated. RESULTS: No differences have been found in clinical or magnetic resonance imaging recurrence of disease activity amongst the groups. Interestingly, no disease reactivation was observed only in one patient treated for 6 months with monthly pulses of cyclophosphamide. CONCLUSION: Disease modifying treatment or 'no treatment' is unable to abolish disease activity reactivation after natalizumab discontinuation.
BACKGROUND AND PURPOSE:Natalizumab discontinuation induces the recurrence of multiple sclerosis disease activity: currently no therapeutic approach has been found able to abolish disease reactivation. METHODS: The recurrence of disease activity after natalizumab discontinuation was retrospectively evaluated in 79 patients who had been treated with immunomodulating agents, other first-line therapies, fingolimod or not treated. RESULTS: No differences have been found in clinical or magnetic resonance imaging recurrence of disease activity amongst the groups. Interestingly, no disease reactivation was observed only in one patient treated for 6 months with monthly pulses of cyclophosphamide. CONCLUSION: Disease modifying treatment or 'no treatment' is unable to abolish disease activity reactivation after natalizumab discontinuation.
Authors: Maria Sepúlveda; Sara Llufriu; Yolanda Blanco; Nuria Solà-Valls; Delon La Puma; Joan Berenguer; Pablo Villoslada; Albert Saiz Journal: J Neurol Date: 2014-11-20 Impact factor: 4.849
Authors: Thomas Roux; Elisabeth Maillart; Jean-Sébastien Vidal; Sophie Tezenas du Montcel; Catherine Lubetzki; Caroline Papeix Journal: Front Neurol Date: 2017-05-05 Impact factor: 4.003
Authors: Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve Journal: Front Immunol Date: 2019-07-11 Impact factor: 7.561
Authors: Michael Auer; Anne Zinganell; Harald Hegen; Gabriel Bsteh; Franziska Di Pauli; Klaus Berek; Elena Fava; Sebastian Wurth; Thomas Berger; Florian Deisenhammer Journal: Sci Rep Date: 2021-12-02 Impact factor: 4.379
Authors: Marianna Lo Re; Marco Capobianco; Paolo Ragonese; Sabrina Realmuto; Simona Malucchi; Paola Berchialla; Giuseppe Salemi; Antonio Bertolotto Journal: Neurol Ther Date: 2015-12-08